Skip to main content

Headache and Neurological Pain

Our research group is focused on studying the pathophysiology of migraine and other primary headaches using preclinical, translational and clinical research.

Migraine will allow us to define the brain’s adaptive, sensory/cognitive functions, through genetics, epigenetics, neurophysiology, neuromolecular and neuroanatomical information with an interest in developing clinical therapeutic solutions, with the goal on having an impact on suffering and increasing the well-being.

Team

Lucia Linquan Carrillo Negredo

Lucia Linquan Carrillo Negredo

Research technician
Headache and Neurological Pain
Read more
Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Eulalia Gine Cipres

Eulalia Gine Cipres

Main researcher
Headache and Neurological Pain
Read more
Laila Asskour

Laila Asskour

Research technician
Headache and Neurological Pain
Read more
Lucia Linquan Carrillo Negredo

Lucia Linquan Carrillo Negredo

Research technician
Headache and Neurological Pain
Read more
Edoardo Caronna

Edoardo Caronna

Postdoctoral researcher
Headache and Neurological Pain
Read more
Eulalia Gine Cipres

Eulalia Gine Cipres

Main researcher
Headache and Neurological Pain
Read more
Laila Asskour

Laila Asskour

Research technician
Headache and Neurological Pain
Read more

Projects

Assessing the role of glial cells in migraine and its chronification

IP: Marta Vila Pueyo
Collaborators: Laila Asskour , Victor José Gallardo Lopez, Erika Ivanna Araya
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 175000
Reference: PID2022-137287NA-I00
Duration: 01/09/2023 - 31/08/2026

Ministerio de Ciencia

Role of microglia in preclinical models of migraine

IP: Marta Vila Pueyo
Collaborators: -
Funding agency: Fundació "La Caixa"
Funding: 305100
Reference: LCF/BQ/PI23/11970015
Duration: 31/12/2023 - 30/12/2026

Blog

News

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research